(Afasevikumab)Biosimilar Reference Antibody-GS40015 新品

货号：GS40015

Afasevikumab (RG7624, RO5553110) is a fully human monoclonal antibody of the IgG1\kappa isotype. It is a dual inhibitor designed to simultaneously neutralize the activity of both Interleukin-17A (IL-17A) and Interleukin-17F (IL-17F). By binding to these key pro-inflammatory cytokines, Afasevikumab prevents them from initiating the inflammatory cascade associated with various autoimmune and inflammatory disorders. This dual mechanism was hypothesized to offer greater clinical efficacy than targeting IL-17A alone. It was investigated in Phase I clinical trials for the treatment of inflammatory diseases like autoimmune disorders but appears to have been discontinued in development.